IMUNON, Inc. announced on August 28, 2025, that it has successfully regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. This confirmation came from the Nasdaq Hearings Panel, ensuring uninterrupted trading of IMUNON common stock on the exchange.
This achievement follows the company's implementation of a compliance plan, which included a 15% stock dividend to shareholders of record as of August 7, 2025. The company's CEO, Stacy Lindborg, Ph.D., stated that this reflects confidence in the clinical pipeline and commitment to rewarding investors.
The regained compliance builds on the positive momentum from the unprecedented Phase 2 OVATION 2 trial results for IMNN-001 and the successful initiation of the Phase 3 OVATION 3 trial in North America. This regulatory milestone provides stability and liquidity for investors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.